JP7670711B2 - ジアリール大環状化合物を含む併用療法 - Google Patents

ジアリール大環状化合物を含む併用療法 Download PDF

Info

Publication number
JP7670711B2
JP7670711B2 JP2022531006A JP2022531006A JP7670711B2 JP 7670711 B2 JP7670711 B2 JP 7670711B2 JP 2022531006 A JP2022531006 A JP 2022531006A JP 2022531006 A JP2022531006 A JP 2022531006A JP 7670711 B2 JP7670711 B2 JP 7670711B2
Authority
JP
Japan
Prior art keywords
alkyl
cancer
compound
kras
inhibits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022531006A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505056A (ja
JP2023505056A5 (https=
Inventor
デン，ウェイ
ジャイ，ダヨン
ロドン，ラウラ
ダブリュー マリー，ブライオン
ジェイ ツイ，ジンロン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Turning Point Therapeutics Inc
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of JP2023505056A publication Critical patent/JP2023505056A/ja
Publication of JP2023505056A5 publication Critical patent/JP2023505056A5/ja
Application granted granted Critical
Publication of JP7670711B2 publication Critical patent/JP7670711B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022531006A 2019-11-27 2020-11-25 ジアリール大環状化合物を含む併用療法 Active JP7670711B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962941026P 2019-11-27 2019-11-27
US62/941,026 2019-11-27
US202062981822P 2020-02-26 2020-02-26
US62/981,822 2020-02-26
US202063005681P 2020-04-06 2020-04-06
US63/005,681 2020-04-06
PCT/US2020/062390 WO2021108682A1 (en) 2019-11-27 2020-11-25 Combination therapy involving diaryl macrocyclic compounds

Publications (3)

Publication Number Publication Date
JP2023505056A JP2023505056A (ja) 2023-02-08
JP2023505056A5 JP2023505056A5 (https=) 2023-12-05
JP7670711B2 true JP7670711B2 (ja) 2025-04-30

Family

ID=76129920

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022531006A Active JP7670711B2 (ja) 2019-11-27 2020-11-25 ジアリール大環状化合物を含む併用療法

Country Status (12)

Country Link
US (2) US11654145B2 (https=)
EP (1) EP4065125A4 (https=)
JP (1) JP7670711B2 (https=)
KR (1) KR20220133866A (https=)
CN (1) CN114901286B (https=)
AU (1) AU2020391222A1 (https=)
BR (1) BR112022010278A2 (https=)
CA (1) CA3162632A1 (https=)
IL (1) IL293206A (https=)
MX (1) MX2022006500A (https=)
TW (1) TW202133855A (https=)
WO (1) WO2021108682A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021154929A1 (en) * 2020-01-31 2021-08-05 Verastem, Inc. Combination therapy for treating abnormal cell growth
US20220323446A1 (en) * 2021-03-17 2022-10-13 Amgen Inc. Sotorasib dosing regimen
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2025148858A1 (zh) * 2024-01-08 2025-07-17 应世生物科技(南京)有限公司 FAK抑制剂和Pan-RAS抑制剂
WO2025157162A1 (zh) * 2024-01-22 2025-07-31 应世生物科技(南京)有限公司 Fak抑制剂与kras g12c抑制剂的联用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017528488A (ja) 2014-09-18 2017-09-28 アラクセス ファーマ エルエルシー がんの処置のための併用療法
JP2018519343A (ja) 2015-07-02 2018-07-19 ティーピー・セラピューティクス・インコーポレイテッドＴｐ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子
WO2018140554A1 (en) 2017-01-25 2018-08-02 Tp Therapeutics, Inc. Combination therapy involving diaryl macrocyclic compounds
JP2018529633A (ja) 2015-07-06 2018-10-11 ティーピー・セラピューティクス・インコーポレイテッドＴｐ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ジアリール大環状多形

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010319322A1 (en) * 2009-11-13 2012-05-31 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
ES2933350T3 (es) * 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
EP3368039A1 (en) * 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US20190134056A1 (en) * 2017-03-10 2019-05-09 The Trustees Of The Stevens Institute Of Technolog K-ras mutations and antagonists
AU2018273356B2 (en) 2017-05-22 2021-09-16 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
LT3710439T (lt) 2017-11-15 2023-05-10 Mirati Therapeutics, Inc. Kras g12c inhibitoriai
JP7060694B2 (ja) * 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
ES3017461T3 (en) 2018-09-10 2025-05-13 Mirati Therapeutics Inc Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
CN110256421A (zh) * 2019-06-26 2019-09-20 微境生物医药科技(上海)有限公司 Kras-g12c抑制剂
MX2022006366A (es) * 2019-11-27 2022-06-22 Turning Point Therapeutics Inc Terapia de combinacion que implica compuestos de diarilo macrociclico.
WO2021148581A1 (en) * 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017528488A (ja) 2014-09-18 2017-09-28 アラクセス ファーマ エルエルシー がんの処置のための併用療法
JP2018519343A (ja) 2015-07-02 2018-07-19 ティーピー・セラピューティクス・インコーポレイテッドＴｐ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子
JP2018529633A (ja) 2015-07-06 2018-10-11 ティーピー・セラピューティクス・インコーポレイテッドＴｐ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ジアリール大環状多形
WO2018140554A1 (en) 2017-01-25 2018-08-02 Tp Therapeutics, Inc. Combination therapy involving diaryl macrocyclic compounds

Also Published As

Publication number Publication date
EP4065125A4 (en) 2024-01-03
JP2023505056A (ja) 2023-02-08
IL293206A (en) 2022-07-01
AU2020391222A1 (en) 2022-06-30
US11654145B2 (en) 2023-05-23
US20240033266A1 (en) 2024-02-01
CA3162632A1 (en) 2021-06-03
CN114901286B (zh) 2024-05-10
WO2021108682A1 (en) 2021-06-03
KR20220133866A (ko) 2022-10-05
MX2022006500A (es) 2022-07-04
CN114901286A (zh) 2022-08-12
EP4065125A1 (en) 2022-10-05
US20210220364A1 (en) 2021-07-22
TW202133855A (zh) 2021-09-16
BR112022010278A2 (pt) 2022-10-04

Similar Documents

Publication Publication Date Title
JP7670711B2 (ja) ジアリール大環状化合物を含む併用療法
KR102064626B1 (ko) Tor 키나제 억제자 복합 치료법을 사용한 비소세포 폐암의 치료 방법
JP7193475B2 (ja) ジアリール大環状化合物を含む併用療法
CN111837146B (zh) G1t38优异剂量方案
KR102271344B1 (ko) 디하이드로피라지노-피라진을 사용한 암의 치료
JP2020528875A (ja) 血小板由来成長因子受容体アルファの遺伝的異常に関連する癌の治療のための、１−［４−ブロモ−５−［１−エチル−７−（メチルアミノ）−２−オキソ−１，２−ジヒドロ−１，６−ナフチリジン−３−イル］−２−フルオロフェニル］−３−フェニルウレアおよびアナログの使用
CN114867622A (zh) 涉及二芳基巨环化合物的组合疗法
KR20180132618A (ko) 아미노티아졸 화합물 및 이의 용도
CN119403808A (zh) 用于医学治疗的细胞周期蛋白依赖性激酶2抑制剂
CN114430681A (zh) 使用egfr和cdk4/6抑制剂的组合治疗egfr突变相关的癌症
EP4441052B1 (en) Compounds
RU2784853C2 (ru) Комбинационная терапия с применением диарильных макроциклических соединений
HK40128998A (zh) 治疗癌症的方法
HK40041180A (en) G1t38 superior dosage regimes
HK1254606B (zh) 手性二芳基大环及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241022

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250325

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250417

R150 Certificate of patent or registration of utility model

Ref document number: 7670711

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150